AR058567A1 - Formulaciones de proteinas estables - Google Patents
Formulaciones de proteinas establesInfo
- Publication number
- AR058567A1 AR058567A1 ARP060105626A ARP060105626A AR058567A1 AR 058567 A1 AR058567 A1 AR 058567A1 AR P060105626 A ARP060105626 A AR P060105626A AR P060105626 A ARP060105626 A AR P060105626A AR 058567 A1 AR058567 A1 AR 058567A1
- Authority
- AR
- Argentina
- Prior art keywords
- ctla4lg
- routes
- formulations
- formulation
- molecules
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 abstract 4
- 238000007920 subcutaneous administration Methods 0.000 abstract 3
- 238000001990 intravenous administration Methods 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000008365 aqueous carrier Substances 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 230000024664 tolerance induction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Formulaciones estables que comprenden las moléculas de CTLA4lg, molécula de proteína que comprende al menos un polipéptico que tiene un dominio extracelular de CTLA4lg o porcion del mismo y una region constante de inmunoglobulina o porcion del mismo, incluyendo las formulaciones liofilizadas y líquidas para la asministracion por medio de diversas rutas incluyendo, por ejemplo, rutas tales como las rutas intravenosa (IV) y subcutánea (SC) para tratar enfermedades del sistema inmune e induccion de tolerancia. Reivindicacion 1: Una formulacion estable, adecuada para la administracion subcutánea, caracterizada porque comprende al menos 100 mg/ml de moléculas de CTLA4lg, un azucar capaz de estabilizar la formulacion a una concentracion efectiva para la misma, y un portador acuoso farmacéuticamente aceptable. Reivindicacion 7: La formulacion de conformidad con la reivincicacion 1, caracterizada porque la molécula de CTLA4lg tiene la secuencia de aminoácidos mostrada en la SEQ ID NO:2 comenzando con la metionina en la posicion 27 o alanina en la posicion 26 y terminando en la lisina en la posicion 383 o glisina en la posicion 382.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75215005P | 2005-12-20 | 2005-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR058567A1 true AR058567A1 (es) | 2008-02-13 |
Family
ID=38057529
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105626A AR058567A1 (es) | 2005-12-20 | 2006-12-19 | Formulaciones de proteinas estables |
| ARP140103315A AR097561A2 (es) | 2005-12-20 | 2014-09-04 | Un método para la obtención de una composición que comprende una población aislada de moléculas del antígeno 4 de linfocito t citotóxico ligado a la región constante de cadena pesada de inmunoglobulina (ctla-ig) a partir de un medio de cultivo líquido |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140103315A AR097561A2 (es) | 2005-12-20 | 2014-09-04 | Un método para la obtención de una composición que comprende una población aislada de moléculas del antígeno 4 de linfocito t citotóxico ligado a la región constante de cadena pesada de inmunoglobulina (ctla-ig) a partir de un medio de cultivo líquido |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8476239B2 (es) |
| EP (1) | EP1962886B2 (es) |
| JP (2) | JP5247467B2 (es) |
| KR (1) | KR101378194B1 (es) |
| CN (3) | CN101822820A (es) |
| AR (2) | AR058567A1 (es) |
| AU (1) | AU2006330593B2 (es) |
| BR (1) | BRPI0622256A2 (es) |
| CA (1) | CA2634547C (es) |
| CL (1) | CL2010000816A1 (es) |
| DK (1) | DK1962886T4 (es) |
| EA (1) | EA014232B1 (es) |
| ES (1) | ES2436616T5 (es) |
| HR (1) | HRP20131196T4 (es) |
| IL (1) | IL192104A (es) |
| NO (1) | NO347247B1 (es) |
| NZ (1) | NZ569108A (es) |
| PE (1) | PE20071063A1 (es) |
| PL (1) | PL1962886T6 (es) |
| PT (1) | PT1962886E (es) |
| RS (1) | RS53127B2 (es) |
| SG (1) | SG153832A1 (es) |
| TW (3) | TW200738261A (es) |
| WO (1) | WO2007076354A2 (es) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007076354A2 (en) * | 2005-12-20 | 2007-07-05 | Bristol-Myers Squibb Company | Stable protein formulations |
| PT1969007E (pt) | 2005-12-20 | 2013-12-10 | Bristol Myers Squibb Co | Composições e métodos para a produção de uma composição |
| US9309316B2 (en) | 2005-12-20 | 2016-04-12 | Bristol-Myers Squibb Company | Stable subcutaneous protein formulations and uses thereof |
| AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
| US7915222B2 (en) | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
| EP4183425A1 (en) | 2008-10-06 | 2023-05-24 | 3-D Matrix Ltd. | Tissue plug |
| EP2445616B1 (en) * | 2009-06-23 | 2018-05-02 | GE Healthcare Bio-Sciences AB | Simulator device |
| GB201009676D0 (en) * | 2010-06-10 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel process |
| JP5847418B2 (ja) | 2011-03-30 | 2016-01-20 | 富士フイルム株式会社 | 細胞接着性タンパク質 |
| WO2012142434A2 (en) * | 2011-04-15 | 2012-10-18 | THE UNITED STATES OF AMERICA, as represented by the secretary, Depart.of Healtth and Human Services | Aav mediated ctla-4 gene transfer to treat sjogren's syndrome |
| EP2709653B1 (en) | 2011-04-20 | 2017-11-22 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity |
| TWI527590B (zh) * | 2011-06-17 | 2016-04-01 | 艾瑞斯貿易公司 | Ｆｇｆ－１８之凍乾調配物 |
| GEP201706608B (en) | 2011-10-07 | 2017-01-25 | Takeda Pharmaceuticals Co | 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases |
| SMT202000091T1 (it) | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
| AR088379A1 (es) | 2011-10-18 | 2014-05-28 | Coherus Biosciences Inc | Formulaciones de etanercept estabilizadas con iones metalicos |
| US10493151B2 (en) | 2011-10-18 | 2019-12-03 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
| JP2015522024A (ja) | 2012-06-29 | 2015-08-03 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 糖タンパク質の凝集を低下させるための方法 |
| WO2014008400A2 (en) | 2012-07-06 | 2014-01-09 | 3-D Matrix, Inc. | Fill-finish process for peptide solutions |
| JP6271536B2 (ja) * | 2012-07-09 | 2018-01-31 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 肉眼不可視粒子の著しい低減を示すエタネルセプト製剤 |
| WO2014036468A2 (en) | 2012-08-31 | 2014-03-06 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Aav mediated aquaporin gene transer to treat sjogren's syndrome |
| SMT202000147T1 (it) | 2012-09-07 | 2020-05-08 | Coherus Biosciences Inc | Formulazioni acquose stabili di adalimumab |
| EA031324B1 (ru) | 2012-09-11 | 2018-12-28 | Кохерус Байосайенсис, Инк. | Правильно свернутый этанерцепт с высокой чистотой и высоким уровнем выхода |
| EP2855533A4 (en) * | 2013-03-15 | 2015-11-25 | Momenta Pharmaceuticals Inc | METHODS RELATING TO CTLA4-FC FUSION PROTEINS |
| US10464996B2 (en) | 2013-05-13 | 2019-11-05 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
| CN103385852B (zh) * | 2013-08-06 | 2015-03-11 | 南京正大天晴制药有限公司 | 一种盐酸法舒地尔注射液及其制备方法 |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| US20160257754A1 (en) | 2013-10-16 | 2016-09-08 | Momenta Pharmaceuticals Inc. | Sialylated glycoproteins |
| RU2016139369A (ru) | 2014-03-10 | 2018-04-10 | 3-Д Матрикс, Лтд. | Композиции самоорганизующихся пептидов |
| US10369237B2 (en) | 2014-03-10 | 2019-08-06 | 3-D Matrix, Ltd. | Sterilization and filtration of peptide compositions |
| US20170051059A1 (en) | 2014-03-19 | 2017-02-23 | Bristol-Myers Squibb Company | Methods of treating transplant rejection using a domain antibody directed against cd40 |
| US11058768B2 (en) * | 2014-04-16 | 2021-07-13 | Biocon Ltd. | Stable protein formulations comprising a molar excess of sorbitol |
| US20170042972A1 (en) | 2014-04-25 | 2017-02-16 | Chetan KARYEKAR | Use of ctla4 compound for achieving drug-free remission in subjects with early ra |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| WO2015196091A1 (en) | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| US20170204149A1 (en) | 2014-06-23 | 2017-07-20 | Novartis Ag | Hsa-gdf-15 fusion polypeptide and use thereof |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| EP3851445A1 (en) | 2014-06-23 | 2021-07-21 | Novartis AG | Site specific protein modifications |
| SG10201902915VA (en) | 2014-10-01 | 2019-04-29 | Eagle Biologics Inc | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| EP3207936B1 (en) | 2014-11-18 | 2021-04-21 | Shionogi & Co., Ltd. | Stable peptide composition |
| BR112017014194A2 (pt) | 2015-01-23 | 2018-01-09 | Novartis Ag | conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada |
| MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| CN107849144B (zh) | 2015-05-29 | 2021-09-17 | 艾吉纳斯公司 | 抗-ctla-4抗体及其使用方法 |
| EP3347031B8 (en) * | 2015-09-11 | 2021-04-28 | Nutrition & Biosciences USA 1, LLC | A composition comprising a protein and a polyalkoxy fatty compound |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| US11058769B2 (en) | 2015-12-07 | 2021-07-13 | Merck Patent Gmbh | Aqueous pharmaceutical formulation comprising anti-PD-L1 antibody Avelumab |
| US20190000923A1 (en) | 2015-12-22 | 2019-01-03 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| WO2017120092A1 (en) | 2016-01-06 | 2017-07-13 | 3-D Matrix, Ltd. | Combination compositions |
| EP3192805A1 (en) | 2016-01-15 | 2017-07-19 | Humanitas Mirasole S.p.A. | Inhibitors of t cell activation or stimulation and uses thereof |
| WO2017184880A1 (en) | 2016-04-20 | 2017-10-26 | Coherus Biosciences, Inc. | A method of filling a container with no headspace |
| IL307242A (en) | 2016-12-07 | 2023-11-01 | Agenus Inc | Anti-CTLA-4 antibodies and methods of using them |
| KR102840867B1 (ko) | 2017-05-24 | 2025-07-30 | 에이엘에스 테라피 디벨럽먼트 인스티튜트 | 치료용 항-cd40 리간드 항체 |
| CN119386161A (zh) | 2017-12-22 | 2025-02-07 | 诺华股份有限公司 | 用fgf21变体治疗代谢障碍的方法 |
| CN108014338A (zh) * | 2018-01-22 | 2018-05-11 | 安徽未名生物医药有限公司 | 一种注射用巴利昔单抗冻干粉针及其制备方法 |
| CN112512562A (zh) * | 2018-05-25 | 2021-03-16 | 雷迪博士实验室有限公司 | CTLA4-Ig融合蛋白制剂 |
| US12428464B2 (en) | 2018-05-25 | 2025-09-30 | Dr. Reddy's Laboratories Limited | Stable fusion protein formulation |
| EP3813791A2 (en) * | 2018-06-26 | 2021-05-05 | Lupin Limited | Stable lyophilized dosage form of protein |
| CN113476484A (zh) * | 2018-06-29 | 2021-10-08 | 武汉纽福斯生物科技有限公司 | 治疗遗传性视神经病变的组合物和方法 |
| CN113396158A (zh) | 2018-11-26 | 2021-09-14 | 诺华股份有限公司 | Lpl-gpihbp1融合多肽 |
| US12466866B2 (en) | 2019-01-15 | 2025-11-11 | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Paris, FRANCE | Mutated interleukin-34 (IL-34) polypeptides and uses thereof in therapy |
| US20220098252A1 (en) | 2019-01-25 | 2022-03-31 | Ospedale San Raffaele S.R.L. | Inhibitor of dux4 and uses thereof |
| GB201913697D0 (en) | 2019-09-23 | 2019-11-06 | King S College London | DAP10/DAP12 fusion polypeptides |
| WO2021127525A1 (en) * | 2019-12-20 | 2021-06-24 | Anthos Therapeutics, Inc. | Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies |
| GB202003277D0 (en) | 2020-03-06 | 2020-04-22 | King S College London | Therapeutic agents |
| GB202007655D0 (en) | 2020-05-22 | 2020-07-08 | King S College London | Chimeric nkg2d protein |
| US20240083970A1 (en) * | 2021-02-01 | 2024-03-14 | Dr. Reddy’S Laboratories Limited | Compositions comprising fusion protein and analytical attributes thereof |
| JP2024511059A (ja) | 2021-03-23 | 2024-03-12 | キングス カレッジ ロンドン | Ｎｋｇ２ｄ、ｃｘｃｒ２、およびｄａｐ１０／ｄａｐ１２融合ポリペプチドを含む組成物ならびにその使用方法 |
| CN113925963B (zh) * | 2021-10-15 | 2023-08-11 | 江苏太平洋美诺克生物药业股份有限公司 | 一种稳定的包含抗cd147单克隆抗体的药物制剂 |
| GB202214120D0 (en) | 2022-09-27 | 2022-11-09 | King S College London | Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof |
| WO2024069420A2 (en) * | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
| EP4389762A1 (en) | 2022-12-23 | 2024-06-26 | Ospedale San Raffaele S.r.l. | Inhibitors of dux4 activity and their use in therapy. |
| WO2025196207A1 (en) | 2024-03-20 | 2025-09-25 | King's College London | Compositions and methods for use in depleting senescent cells and treating aging |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ262634A (en) * | 1993-02-23 | 1997-02-24 | Genentech Inc | Stabilizing polypeptides against degradation by organic solvents by admixing the peptide with trehalose or mannitol |
| DE4405426A1 (de) | 1994-02-21 | 1995-08-24 | Boehringer Mannheim Gmbh | Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| ES2434840T3 (es) * | 1995-07-27 | 2013-12-17 | Genentech, Inc. | Formulación de proteína liofilizada isotónica estable |
| WO2003005465A1 (en) | 2001-04-25 | 2003-01-16 | Quallion, Llc | Rechargeable lithium battery for tolerating discharge to zero volts |
| US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| US7183376B2 (en) | 2000-06-23 | 2007-02-27 | Maxygen, Inc. | Variant B7 co-stimulatory molecules |
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| CZ303959B6 (cs) * | 2000-07-03 | 2013-07-17 | Bristol-Myers Squibb Company | Solubilní CTLA4 fúzní molekula, farmaceutický prostredek s jejím obsahem a její pouzití |
| JP2004535364A (ja) | 2001-01-26 | 2004-11-25 | エモリー・ユニバーシティ | 臓器移植の免疫寛容を誘発し、異常血色素症を処置する方法 |
| ATE482716T1 (de) | 2001-11-13 | 2010-10-15 | Genentech Inc | Zusammensetzungen basierend auf apo2-ligand/ trail und ihre verwendung |
| DE10163459A1 (de) * | 2001-12-21 | 2003-07-03 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor |
| DE10204792A1 (de) * | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Immuncytokine |
| CN101721362B (zh) | 2002-02-14 | 2018-07-03 | 中外制药株式会社 | 包含抗体的溶液制剂 |
| ES2354610T5 (es) | 2002-12-23 | 2020-09-14 | Bristol Myers Squibb Co | Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína |
| AU2003300276B2 (en) | 2002-12-23 | 2010-07-01 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| EP3178492A1 (en) * | 2003-04-04 | 2017-06-14 | Genentech, Inc. | High concentration antibody and protein formulations |
| RU2353384C2 (ru) | 2003-08-04 | 2009-04-27 | Бристол-Маерс Сквибб Компани | Способ лечения сердечно-сосудистого заболевания с применением растворимого ctla4 |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| AU2006295340B2 (en) * | 2005-08-05 | 2010-11-11 | Amgen Inc. | Stable aqueous protein or antibody pharmaceutical formulations and their preparation |
| WO2007076354A2 (en) * | 2005-12-20 | 2007-07-05 | Bristol-Myers Squibb Company | Stable protein formulations |
-
2006
- 2006-12-19 WO PCT/US2006/062297 patent/WO2007076354A2/en not_active Ceased
- 2006-12-19 PT PT68466838T patent/PT1962886E/pt unknown
- 2006-12-19 EP EP06846683.8A patent/EP1962886B2/en active Active
- 2006-12-19 CN CN200910139825A patent/CN101822820A/zh active Pending
- 2006-12-19 PE PE2006001649A patent/PE20071063A1/es active IP Right Grant
- 2006-12-19 US US12/086,876 patent/US8476239B2/en active Active
- 2006-12-19 ES ES06846683T patent/ES2436616T5/es active Active
- 2006-12-19 BR BRPI0622256-0A patent/BRPI0622256A2/pt not_active Application Discontinuation
- 2006-12-19 AU AU2006330593A patent/AU2006330593B2/en active Active
- 2006-12-19 KR KR1020087017544A patent/KR101378194B1/ko active Active
- 2006-12-19 NZ NZ569108A patent/NZ569108A/en unknown
- 2006-12-19 PL PL06846683.8T patent/PL1962886T6/pl unknown
- 2006-12-19 DK DK06846683.8T patent/DK1962886T4/da active
- 2006-12-19 SG SG200904148-4A patent/SG153832A1/en unknown
- 2006-12-19 TW TW095147647A patent/TW200738261A/zh unknown
- 2006-12-19 HR HRP20131196TT patent/HRP20131196T4/hr unknown
- 2006-12-19 CN CNA2009101398246A patent/CN101584858A/zh active Pending
- 2006-12-19 NO NO20082628A patent/NO347247B1/no unknown
- 2006-12-19 JP JP2008547721A patent/JP5247467B2/ja active Active
- 2006-12-19 TW TW098139142A patent/TWI393575B/zh active
- 2006-12-19 TW TW098139141A patent/TW201008595A/zh unknown
- 2006-12-19 EA EA200801570A patent/EA014232B1/ru active Protection Beyond IP Right Term
- 2006-12-19 CA CA2634547A patent/CA2634547C/en active Active
- 2006-12-19 CN CN2006800530514A patent/CN101378773B/zh active Active
- 2006-12-19 AR ARP060105626A patent/AR058567A1/es not_active Application Discontinuation
- 2006-12-20 RS RS20130553A patent/RS53127B2/sr unknown
-
2008
- 2008-06-12 IL IL192104A patent/IL192104A/en active IP Right Grant
-
2010
- 2010-07-30 CL CL2010000816A patent/CL2010000816A1/es unknown
-
2011
- 2011-06-27 JP JP2011141983A patent/JP5538309B2/ja active Active
-
2014
- 2014-09-04 AR ARP140103315A patent/AR097561A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR058567A1 (es) | Formulaciones de proteinas estables | |
| de Lencastre Novaes et al. | Stability, purification, and applications of bromelain: A review | |
| PE20231439A1 (es) | Proteinas f de hmpv estabilizadas por prefusion | |
| CY1124265T1 (el) | Σκευασματα ανταγωνιστη vegf καταλληλα για ενδοϋαλωδη χορηγηση | |
| CY1118467T1 (el) | Σκευασματα αντισωματων και πρωτεϊνων υψηλης συγκεντρωσης | |
| FI2970398T3 (fi) | Rsv f -prefuusioproteiineja ja niiden käyttö | |
| AR092400A1 (es) | Formulaciones de anticuerpos y proteinas de alta concentracion | |
| AR038568A1 (es) | Anticuerpos anti-a beta y su uso | |
| ES2980738T3 (es) | Composición para uso en un método inmunoestimulador | |
| AR107020A2 (es) | Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) | |
| CA2846598A1 (en) | Treatment of degenerative joint disease | |
| EA200601169A1 (ru) | Конъюгаты иммуногенных пептидных носителей и способы их получения | |
| EP2694708A2 (en) | Formulations with reduced viscosity | |
| AR068020A1 (es) | Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico | |
| CN113423722A (zh) | 用于胞吞转运的递送构建体及相关方法 | |
| US20230158100A1 (en) | Treatment of panx1 associates diseases | |
| BRPI0607097A2 (pt) | peptìdeos de papiloma vìrus l2 n-terminais para a indução de anticorpos de neutralização amplamente cruzada | |
| BRPI0406745A (pt) | Formulações parenterais de peptìdeos para o tratamento de lupus eritematoso sistêmico | |
| AR035077A1 (es) | Polipeptidos de neublastina variante, proteinas de fusion, acidos nucleicos, vectores, celulas hospedadoras, metodos para producir dichos polipeptidos, dimeros, conjugados, composiciones farmaceuticas y uso de dichos polipeptidos en la preparacion de medicamentos | |
| RU2019113989A (ru) | Лекарственное средство | |
| DK1079849T3 (da) | Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning | |
| WO2006052821A3 (en) | Compositions and methods for treatment of protein misfolding and protein aggregation diseases | |
| Choi et al. | Construction and characterization of cell-penetrating peptide-fused fibroblast growth factor and vascular endothelial growth factor for an enhanced percutaneous delivery system | |
| ATE552271T1 (de) | Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon | |
| KR20080080079A (ko) | 샤페로닌 10에 의해 유도되는 면역조절 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |